MOLECULAR CONTROL OF RETINAL STEM CELL DEVELOPMENT

视网膜干细胞发育的分子控制

基本信息

  • 批准号:
    6164718
  • 负责人:
  • 金额:
    $ 10.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-03-01 至 2003-02-28
  • 项目状态:
    已结题

项目摘要

Commitment of cells to form a retina occurs during early embryogenesis as the neural plate is regionalized into specific domains. Once specified to become retina, the precursor cells proliferate as stem cells until signaled to stop dividing and differentiate. Retinal stem cells are multipotent, giving rise to all of the cells of the pigmented and neural retina, and are capable of participating in retinal regeneration in lower vertebrates. We have chosen to study genes likely to control retinal stem cell fate in an effort to determine the molecular mechanisms that control the establishment and proliferation of the retina. Several homeobox-containing trasncriptional regulatory genes are important for the proper formation of the eye during embryonic development, including Pax6, Chx10 and Lhx2. A new family of retinal homeobox genes, Rx, is expressed in a spatial and temporal pattern consistent with a role in retinal stem cell specification and proliferation. The function of the Rx gene is crucial for proper eye formation, as overexpression causes hyperproliferation of the neural retina and retinal pigment epithelium, and targeted deletion of the Rx gene in the mouse eliminates optic vesicle formation and results in the birth of eyeless mouse pups. Our proposed studies are aimed at identifying the mechanisms by which Rx regulates early mammalian eye development. We have designed three strategies in different experimental systems to study the role of Rx during retinal formation, proliferation and differentiation. Using gene expression studies in mice carrying different ocular mutations, we will investigate whether Rx is necessary for the initial specification of retinal cell fate. An analysis of later Rx function during retinal stem cell proliferation and differentiation will be performed using molecular techniques in primary mouse retinal cultures and human retinoblastoma cells. Finally, we propose to screen DNA samples from anophthalmic patients for mutations in the human Rx gene. These experiments will elucidate the role of the Rx homeobox gene in human eye development. The proposed studies have important implications for our basic understanding of ocular organogenesis, and may contribute to medical treatment strategies for retinoblastoma, retinal degeneration and anophthalmia.
形成视网膜的细胞发生在胚胎发生的早期

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter H Mathers其他文献

Peter H Mathers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter H Mathers', 18)}}的其他基金

TRANSGENIC ANIMAL CORE
转基因动物核心
  • 批准号:
    8364956
  • 财政年份:
    2011
  • 资助金额:
    $ 10.21万
  • 项目类别:
COBRE: WVU: MOLECULAR REGULATION OF TONOTOPIC ORGANIZATION
COBRE:WVU:主题组织的分子调控
  • 批准号:
    7170286
  • 财政年份:
    2005
  • 资助金额:
    $ 10.21万
  • 项目类别:
COBRE: WVU: MOLECULAR REGULATION OF TONOTOPIC ORGANIZATION
COBRE:WVU:主题组织的分子调控
  • 批准号:
    7011721
  • 财政年份:
    2004
  • 资助金额:
    $ 10.21万
  • 项目类别:
MOLECULAR CONTROL OF RETINAL STEM CELL DEVELOPMENT
视网膜干细胞发育的分子控制
  • 批准号:
    6363162
  • 财政年份:
    1998
  • 资助金额:
    $ 10.21万
  • 项目类别:
MOLECULAR CONTROL OF RETINAL STEM CELL DEVELOPMENT
视网膜干细胞发育的分子控制
  • 批准号:
    2605218
  • 财政年份:
    1998
  • 资助金额:
    $ 10.21万
  • 项目类别:
MOLECULAR CONTROL OF RETINAL STEM CELL DEVELOPMENT
视网膜干细胞发育的分子控制
  • 批准号:
    6518589
  • 财政年份:
    1998
  • 资助金额:
    $ 10.21万
  • 项目类别:
Molecular control of retinal stem cell development
视网膜干细胞发育的分子控制
  • 批准号:
    6870407
  • 财政年份:
    1998
  • 资助金额:
    $ 10.21万
  • 项目类别:
Molecular control of retinal stem cell development
视网膜干细胞发育的分子控制
  • 批准号:
    7176755
  • 财政年份:
    1998
  • 资助金额:
    $ 10.21万
  • 项目类别:
Molecular control of retinal stem cell development
视网膜干细胞发育的分子控制
  • 批准号:
    7009195
  • 财政年份:
    1998
  • 资助金额:
    $ 10.21万
  • 项目类别:
MOLECULAR CONTROL OF RETINAL STEM CELL DEVELOPMENT
视网膜干细胞发育的分子控制
  • 批准号:
    2882947
  • 财政年份:
    1998
  • 资助金额:
    $ 10.21万
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 10.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    $ 10.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    $ 10.21万
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    $ 10.21万
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 10.21万
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    $ 10.21万
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    $ 10.21万
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    $ 10.21万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 10.21万
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    $ 10.21万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了